Skip to Content

6 Results Found

  • Article
  • Open Access
51 Citations
6,692 Views
15 Pages

Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression

  • John D. Klement,
  • Dakota B. Poschel,
  • Chunwan Lu,
  • Alyssa D. Merting and ,
  • Dafeng Yang,
  • Priscilla S. Redd and
  • Kebin Liu
  • + 2 authors+ 0 author

28 February 2021

Human colorectal cancers are mostly microsatellite-stable with no response to anti-PD-1 blockade immunotherapy, necessitating the development of a new immunotherapy. Osteopontin (OPN) is elevated in human colorectal cancer and may function as an immu...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
132 Citations
13,350 Views
31 Pages

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation

  • Hannah R. Moorman,
  • Dakota Poschel,
  • John D. Klement,
  • Chunwan Lu and ,
  • Priscilla S. Redd and
  • Kebin Liu
  • + 1 author+ 0 author

15 November 2020

OPN is a multifunctional phosphoglycoprotein expressed in a wide range of cells, including osteoclasts, osteoblasts, neurons, epithelial cells, T, B, NK, NK T, myeloid, and innate lymphoid cells. OPN plays an important role in diverse biological proc...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
20 Citations
5,990 Views
18 Pages

Targeted siRNA Nanoparticles for Mammary Carcinoma Therapy

  • Meital Ben-David-Naim,
  • Arie Dagan,
  • Etty Grad,
  • Gil Aizik and ,
  • Mirjam M. Nordling-David,
  • Alisa Morss Clyne,
  • Zvi Granot and
  • Gershon Golomb
  • + 3 authors+ 0 author

29 March 2019

Non-viral, polymeric-based, siRNA nanoparticles (NPs) have been proposed as promising gene delivery systems. Encapsulating siRNA in targeted NPs could confer improved biological stability, extended half-life, enhanced permeability, effective tumor ac...

(This article belongs to the Special Issue Cancer Nanomedicine)
  • Article
  • Open Access
15 Citations
5,882 Views
18 Pages

Overcoming Irinotecan Resistance by Targeting Its Downstream Signaling Pathways in Colon Cancer

  • Shashank Saurav,
  • Sourajeet Karfa,
  • Trung Vu,
  • Zhipeng Liu and ,
  • Arunima Datta,
  • Upender Manne,
  • Temesgen Samuel and
  • Pran K. Datta
  • + 3 authors+ 0 author

15 October 2024

Among the most popular chemotherapeutic agents, irinotecan, regarded as a prodrug belonging to the camptothecin family that inhibits topoisomerase I, is widely used to treat metastatic colorectal cancer (CRC). Although immunotherapy is promising for...

(This article belongs to the Special Issue Overcoming Chemoresistance in Cancer: Identifying Biomarkers and Novel Targets)
  • Article
  • Open Access
6 Citations
3,118 Views
16 Pages

Portable Fluorescence Microarray Reader-Enabled Biomarker Panel Detection System for Point-of-Care Diagnosis of Lupus Nephritis

  • Aygun Teymur,
  • Iftak Hussain,
  • Chenling Tang,
  • Ramesh Saxena and ,
  • David Erickson and
  • Tianfu Wu
  • + 1 author+ 0 author

29 January 2025

Point-of-care (POC) testing has revolutionized diagnostics by providing rapid, accessible solutions outside traditional laboratory settings. However, many POC systems lack the sensitivity or multiplexing capability required for complex diseases. This...

(This article belongs to the Section B4: Point-of-Care Devices)
  • Article
  • Open Access
1 Citations
1,149 Views
18 Pages

Annexin A6 Modulates the Secretion of Pro-Inflammatory Cytokines and Exosomes via Interaction with SNAP23 in Triple-Negative Breast Cancer Cells

  • Nobelle I. Sakwe,
  • Olga Y. Korolkova,
  • Ngoc B. Vuong,
  • Alayjha D. Edwards and ,
  • Perrin J. Black,
  • Destiny D. Ball,
  • Antonisha R. McIntosh,
  • Portia L. Thomas,
  • Diva S. Whalen Melvin and
  • Amos M. Sakwe
  • + 8 authors+ 3 authors

31 May 2026

Annexin A6 (AnxA6) is a predominantly intracellular calcium-dependent membrane-binding multifunctional protein that is also detected extracellularly and in small extracellular vesicles (exosomes). We previously demonstrated that lapatinib resistance...